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ABSTRACT Heat-sensitive immunoliposomes are capable
of releasing the entrapped content at the target cell surface
upon a brief heating to the phase transition temperature of the
liposome membrane. In this study we have examined the
delivery efficiency of drugs entrapped in heat-sensitive im-
munoliposomes. Immunoliposomes composed of dipalmitoyl
phosphatidylcholine with entrapped [3H]uridine were incubat-
ed with target cells at 40C. The cell-4iposome mixture was then
heated to 410C and the uptake of [3H]uridine into the intra-
cellular pool of phosphorylated uridine-containing molecules
was measured. The immunoliposomes showed maximal release
of the uridine at 41'C, the phase transition temperature of
dipalmitoyl phosphatidylcholine liposomes. The largest accu-
mulation of [3H]uridine in the target cells also took place at
41PC. The initial level of uptake of [3H]uridine released from
immunoliposomes by heating was greatly enhanced over that
observed for free [3H]uridine and [3H]uridine released from
liposomes without attached antibody. The nucleoside uptake
inhibitors nitrothiobenzylinosine, dipyridamole, and unlabeled
uridine were able to inhibit uptake of [3H]uridine released from
immunoliposomes. This supports the hypothesis that the en-
hanced uptake is due to a heat-induced release of [3H]uridine
at the cell surface followed by transport and phosphorylation
of [3H]uridine by the target cells. These results indicate the
feasibility of using the heat-sensitive immunoliposomes as a
target-specific drug delivery system.
Liposomes have been used as carriers for a wide variety of
biologically active materials (1-5). Attachment of monoclo-
nal antibodies to the liposome surface has resulted in specific
binding of the liposomes to cells expressing a cell surface
antigen (for reviews see refs. 6 and 7). Upon binding, the
liposomes are internalized and delivered to the lysosomes
(8-11). The delivered drug must be able to escape this
degrading organelle into the cytosol to exert its therapeutic
effect. Although this type of liposome delivery system has
been effective in a few cases, it is inefficient for most of the
commonly used drugs. To increase the delivery efficiency,
site-directed liposomes with special functions have been
developed.
pH-sensitive liposomes are one type of special-function
liposomes that are capable of fusing with the endosomal
membrane upon acidification of the endocytic vacuole,
thereby releasing its entrapped contents into the cytoplasm
(12-14). However, this mechanism, although quite novel and
very successful, is dependent upon endocytosis of the lipo-
somes by the target cells. Efficient delivery of immunolipo-
some-encapsulated drugs to cells that do not actively
endocytose requires an alternative approach. Heat-sensitive
liposomes have been shown to potentially fulfill this need
(15-18). Attachment of antibody to the heat-sensitive lipo-
somes maintains target cell specificity with respect to bind-
ing. Once bound to the target cell, these immunoliposomes
are able to release their entrapped contents upon heating to
the phase transition temperature of the liposomal lipid. The
advantage arises from the formation of a large localized
concentration of drug at the target cell surface, which serves
to enhance drug uptake over that of drug released into the
bulk medium.
In the initial characterization of these immunoliposomes,
the fluorescent dye carboxyfluorescein was used to monitor
the release properties (19). This dye was not transported by
the cells (20) and therefore, the delivery efficiency could not
be evaluated. In this report we examine delivery efficiency,
using uridine uptake as a model system for delivery of
cytotoxic nucleosides. Nucleoside transport was chosen for
three reasons. First, nucleoside transport is rapid and there-
fore able to take advantage of a high localized concentration
created at the cell surface. Second, nucleoside metabolism
has been well characterized with respect to kinetic parame-
ters and availability ofinhibitors. Third, information obtained
from uridine delivery can be directly applied to the delivery
of chemotherapeutic nucleoside analogues such as 1-,B-D-
arabinofuranosylcytosine, which has similar uptake charac-
teristics (21). We report here the enhanced uptake of uridine
released from immunoliposomes bound to the target cells.
MATERIALS AND METHODS
Reagents. Isolation, iodination, and derivatization of
mouse monoclonal anti-H2Kk IgG with the palmitic acid ester
ofN-hydroxysuccinimide have previously been described (8,
19, 22). Monoclonal P3 IgG was purified from ascites fluid of
mice bearing intraperitoneal P3-X63-Ag8 cells. This IgG has
unknown binding specificity and does not bind with RDM4
cells. It was used as a control IgG. Dipalmitoyl phospha-
tidylcholine (Pam2-PtdCho) was purchased from Avanti Polar
Lipids and stored in CHC13 under N2 at -20°C. Phosphate
was determined by the method of Bartlet (23). [3H]Hexadecyl
cholestanyl ether was used as a lipid marker (24). Uridine was
purchased from Sigma. [3H]Uridine was purchased from
ICN. S-(4-Nitrobenzyl)-6-thioinosine was purchased from
Aldrich. Dipyridamole [2,6-bis(diethanolamino)-4,8-dipiperi-
dinopyrimido[5,4-d]pyrimidine] was obtained from Boeh-
ringer Mannheim. Deoxycholate was purchased from Cal-
biochem and recrystallized twice.
Preparation of Immunoliposomes with Entrapped Uridine.
Immunoliposomes were prepared as previously described
(19). Briefly, small unilamellar liposomes composed of Pam2-
PtdCho were prepared and allowed to fuse at 40C for 3-30
days. The large liposomes were separated from smaller ones
by using a 35-ml preparative 5-20% continuous sucrose
Abbreviation: Pam2-PtdCho, dipalmitoyl phosphatidylcholine.
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density gradient centrifuged at 80,000 x g for 18 hr. A 27 mM
Pam2-PtdCho liposome suspension was prepared in Ca2+-
and Mg2+-free phosphate-buffered saline containing 50 mM
[3H]uridine, 1 mM EGTA, and 0.02% NaN3. The [3H]uridine
specific activity was 2-4 x 105 cpm/nmol. The suspension
was placed in a temperature-regulated chamber set at 41TC.
A 15-mg/ml solution of palmitoyl-specific antibody in phos-
phate-buffered saline containing 3.8 mM deoxycholate, pH
8.0, was injected into the liposome suspension at a rate of0.26
/.l/min by using an infusion pump. The suspension was
annealed at 43TC for 20 min and equilibrated to room
temperature over a period of 20 min. The suspension was
dialyzed overnight against phosphate-buffered saline con-
taining 1 mM EGTA and 0.02% NaN3 to remove untrapped
[3H]uridine and residual deoxycholate. Unincorporated
palmitoyl antibody was removed by the same centrifugation
procedure used to fractionate the stock Pam2-PtdCho lipo-
somes. The uridine/antibody peak was pooled and dialyzed
to remove sucrose. "Bare liposomes" (without attached
palmitoyl antibody) were prepared in the same fashion as the
immunoliposomes except that only phosphate-buffered
saline/3.8 mM deoxycholate was injected into the liposome
suspension. Bare liposomes had the same trapping efficiency
as immunoliposomes. Prior to cell incubation, im-
munoliposomes and bare liposomes were dialyzed against
culture media without serum to remove NaN3.
Determination of Uridine Uptake. RDM4 cells were cul-
tured in RPMI 1640 medium supplemented with 1 mM sodium
pyruvate and 10% fetal bovine serum. For incubation with
liposomes, cells were collected by centrifugation at 500 rpm
for 5 min in a desk-top centrifuge. Cells were resuspended in
cell culture medium containing 10%6 dialyzed donor bovine
serum to a concentration of 2 x 107 cells per ml. Then 0.5 ml
of cell suspension was added to a 6-ml culture tube and
allowed to equilibrate to 4°C for 10 min. One microgram of
immunoliposome-bound palmitoyl antibody, equivalent to 34
,ug of Pam2PtdCho, was added to the RDM4 cells and
incubated at 4°C for 1 hr. This was followed by an 18°C
incubation for 10 min. The incubation mixture was then
diluted to a final volume of 4 ml with culture medium and
placed in a 42.5°C water bath. Because it took about 1 min to
reach 41°C, free [3H]uridine was added to control cells after
the cell suspension was placed in the water bath for 1 min.
The amount of free [3H]uridine added was equal to that
released from the immunoliposomes, which was previously
determined. After heating for the designated time, the sam-
ples were placed in ice and centrifuged at 1000 x g for 10 min.
The 3H cpm released into supernatant was measured. Pellets
were frozen in an ethanol/dry ice bath, thawed and solubil-
ized with 1% Triton X-100 containing 10 mM unlabeled
uridine, and applied to DEAE-cellulose filters (Whatman
DE-81). The filters were washed four times with 500 ml of 10
mM ammonium formate and twice with 500 ml of water.
Filters were incubated overnight with 1 ml of Protosol tissue
solubilizer (New England Nuclear) and radioactivity was
measured with 10 ml of toluene-based scintillation fluor.
Determination of Temperature-Dependent Uridine Release
and Uptake. The protocol was the same as above except that
after the 10-min incubation at 18°C, cells were incubated for
5 min at the designated temperature and then placed on ice.
Percent release was monitored according to Magin and Morse
(25). A 0.2-ml sample of suspension was centrifuged at
200,000 x g for 20 min to pellet the cells and liposomes. The
3H cpm in the supernatant and the pellet were measured to
determine the percent [3H]uridine release.
Inhibition of Uridine Uptake by Nucleoside Transport In-
hibitors. The incubation conditions were the same as used for
uptake measurements with the following modifications. After
the 10-min incubation at 18TC, the cell suspension was diluted
to 4 ml with cell culture medium containing the inhibitor and
incubation at 18'C was continued for another 10 min before
heating.
RESULTS
Phosphorylation of uridine occurs only intracellularly and is
therefore a good criterion for examining the efficiency of
uridine delivery by the immunoliposomes. Uridine transport
and metabolism are collectively referred to as "uptake."
Specifically, the uptake process involves diffusion of extra-
cellular nucleosides across the plasma membrane via a
transport system, followed by the intracellular kinase-
catalyzed phosphorylation of transported uridine. An assay
was developed that measured all phosphorylated uridine
metabolites, including UMP, UDP, UTP, UDP-glucose, and
RNA. Phosphorylated uridine metabolites were collected on
an anion-exchange filter and unphosphorylated uridine was
washed away. This assay and paper chromatographic anal-
ysis of perchloric acid-soluble material (26) yielded compa-
rable results (data not shown).
Temperature-Dependent Release of Uridine from Im-
munoliposomes. Heat-sensitive immunoliposomes were pre-
pared containing 50 mM [3H]uridine. Incubation with i07
RDM4 cells yielded 15-20% of palmitoyl antibody bound and
5-8% of [3H]uridine bound. A 50-fold excess offree antibody
was able to inhibit the palmitoyl antibody binding and
[3H]uridine binding (data not shown). This demonstrated the
cell-associated uridine to be the result of immunoliposome
binding and not due to uptake of released uridine during the
incubation. Release of [3H]uridine from heat-sensitive im-
munoliposomes bound to RDM4 cells is shown in Fig. 1.
Below 41°C, negligible amounts of [3H]uridine had been
released from the immunoliposomes. It was only at 41°C or
above that the maximal amount of [3H]uridine release was
observed. No further increase in percent release was ob-
served above 41°C. These results demonstrate the ability of
the heat-sensitive immunoliposomes to release uridine upon
heating, and they also closely resemble our results for release
of carboxyfluorescein from the same immunoliposome sys-
tem (19).
Uptake of Free Uridine and Uridine Released from Im-
munoliposomes and Bare Liposomes. Shown in Fig. 2 is the
uptake of free [3H]uridine and [3H]uridine released from
heat-sensitive immunoliposomes or heat-sensitive bare lipo-
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FIG. 1. Temperature-dependent release and uptake of uridine.
Cells were incubated with immunoliposomes containing [3H]uridine
for 1 hr at 40C. After 10 min at 18'C, they were heated to the indicated
temperature and incubated for 5 min. Aliquots of cell suspension
were analyzed for percent uridine release (o) and the remainder ofthe
cells was analyzed for uridine uptake (bars).
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FIG. 2. Kinetics of uptake of free [3H]uridine (r) and [3H]uridine
released from immunoliposomes (X) and bare liposomes (o). Zero
time was 1 min after the cell suspension was placed in the heating
bath. Straight lines are linear regressions of data points (±SD) with
r values of 0.83, 0.99, and 0.98 for immunoliposomes, bare lipo-
somes, and free uridine, respectively.
somes as a function of time. When the cell suspension was
first placed in the water bath, there was a 1-min + 10-sec lag
period before the suspension reached the release tempera-
ture-i.e., 41'C. Since the exact zero time for release was
uncertain, we have chosen to indicate the "zero time" in the
figure as 1 min after the cell suspension was placed in the
water bath. Furthermore, the data for the four time points for
each of the three conditions are fitted with straight lines by
linear regression and extrapolated to zero time to estimate the
accumulation of phosphorylated [3H]uridine at the initial
period of release. For release of [3H]uridine from im-
munoliposomes, 17.5 pmol of phosphorylated uridine per 107
cells was observed at the initial time of release. The rate of
uptake after 1 min (slope of the regression line) was 3.0
pmol/min. The initial accumulation of the phosphorylated
uridine for the bare liposomes and free uridine was negligibly
small. The later rate of uptake of [3H]uridine released from
bare liposomes was 2.4 pmol/min and the rate of uptake for
free [3H]uridine was 1.2 pmol/min. Therefore, a significantly
higher initial accumulation ofthe phosphorylated uridine was
observed for immunoliposome-released [3H]uridine as com-
pared with that released from the bare liposomes or the free
[3H]uridine. No enhanced intracellular accumulation was
observed for free uridine in the presence of empty im-
munoliposomes or for uridine released from P3 immuno-
liposomes (results not shown). The subsequent uptake rates
were not significantly different from one another. These
results clearly illustrate that the delivery of encapsulated
contents by the heat-sensitive immunoliposomes is enhanced
only in the initial period of heating.
The temperature dependence for this enhanced uptake of
immunoliposome-released [3H]uridine is shown in Fig. 1.
Below 350C, negligible amounts of [3H]uridine were released
from the immunoliposomes. Consequently, only background
levels of [3H]uridine uptake were observed. Above 41'C,
maximal [3H]uridine release from the bound immunolipo-
somes was observed. The largest accumulation of
phosphorylated [3H]uridine metabolites was also observed at
this temperature range. In a control experiment, free
[3H]uridine uptake showed a gradual increase in the uptake
rate as a function of temperature, but no abrupt increase was
observed at 41'C (data not shown). A decrease in uptake of
immunoliposome-released [3H]uridine was observed at 430C.
This decreased rate of uptake was also observed for free
[3H]uridine. These results show that the enhanced uridine
uptake took place at temperatures at which uridine release
from the cell-bound immunoliposomes was maximal. Fur-
thermore, the enhanced uptake was due to [3H]uridine
released from the immunoliposomes and not due to temper-
ature-dependent stimulation of the uptake process itself.
Inhibition of Uridine Uptake. The mode of entry for the
released [3H]uridine was examined by using three types of
nucleoside uptake inhibitors: nitrothiobenzylinosine (K1 = 1
nM), dipyridamole (Ki = 12 AM from the intercept; K1 = 3 ,M
from the slope) (27, 28), and unlabeled uridine. The results
are shown in Fig. 3, in which A represents inhibition by
unlabeled uridine, B represents inhibition by nitrothio-
benzylinosine, and C represents inhibition by dipyridamole.
Inhibitor was added during the dilution of the cell incubation
mixture to 4 ml and was allowed to incubate with the cells an
additional 10 min at 18TC. The additional incubation time did
not affect the percent of immunoliposomes bound to the
target cells (data not shown). Estimation of the concentration
necessary to produce 50% inhibition of [3H]uridine uptake
yielded 35 ,M unlabeled uridine for immunoliposomes and 5
,uM for free [3H]uridine, 79 nM nitrothiobenzylinosine for
immunoliposomes and 5 nM for free [3H]uridine, and 16 ,uM
dipyridamole for immunoliposomes and 2 ,uM for free [3H]-
uridine. In summary, these results show that uptake of
uridine released from immunoliposomes can be inhibited by
various nucleoside uptake inhibitors. Also, the concentration
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FIG. 3. Inhibition of uptake of immunoliposome-released (e) and
free (0) [3H]uridine by nucleoside transport inhibitors. Data are
expressed as percent of uptake in control cells that had not been
treated with inhibitors.
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of inhibitor necessary to produce 50% inhibition was consid-
erably greater for the immunoliposomes than for free
[3H]uridine, with nitrothiobenzylinosine exhibiting the larg-
est concentration differential.
DISCUSSION
Previously, heat-sensitive liposomes have been used to
deliver chemotherapeutic drugs to implanted tumors in vivo
(17, 18). Localized heating of the tumor produced a signifi-
cant increase in the accumulation of drug released from the
heat-sensitive immunoliposomes over that of the controls
(16, 17). However, only temporary inhibition oftumor growth
was observed (17, 18). It is obvious that by improving the
delivery efficiency, the therapeutic index should be increased
and the subsequent deleterious effects should be diminished.
The main thrust of this research was to show that enhanced
cellular uptake of uridine can be achieved by release of
uridine at the cell surface as opposed to release at a point
distant from the cell surface or simply free in solution. This
point was strongly made by the design of the experiment in
that the majority (95%) of immunoliposomes were unbound
and not removed from the cell suspension prior to heating.
Both unbound and bound immunoliposomes have the same
release properties and therefore, upon heating, most of the
uridine was released into the bulk medium from the unbound
immunoliposomes. However, a large accumulation of
phosphorylated uridine was observed during the initial period
of release from the immunoliposomes, whereas little or no
accumulation was observed for [3H]uridine released from
bare liposomes or for free [3H]uridine. These results show a
local high concentration of uridine released from a small
number of bound immunoliposomes made a significant im-
provement in cellular uptake of uridine.
The mode of the enhanced uptake was examined by using
the uridine uptake inhibitors nitrothiobenzylinosine,
dipyridamole, and unlabeled uridine. Nitrothiobenzylinosine
is an inosine analog and a potent competitive inhibitor of
nucleoside transport (20, 27-29). Dipyridamole, sometimes
referred to as Persantine, is a noncompetitive inhibitor that
yields mixed type inhibition for uridine transport (21). Ad-
dition ofunlabeled uridine inhibited the uptake by decreasing
the specific activity of the entrapped radiolabeled uridine
upon release from the immunoliposomes. The results shown
in Fig. 3 indicate that approximately an 8-fold greater
concentration was required for unlabeled uridine or dipyrid-
amole to inhibit the uptake of immunoliposome released
[3H]uridine. A 16-fold concentration difference was obtained
for nitrothiobenzylinosine. Release of uridine at the cell
surface would create a higher concentration at the cell
surface compared to the medium and would therefore require
a higher concentration of inhibitor for a similar level of
inhibition. These results support the premise that enhance-
ment of uptake of drug delivered by heat-sensitive im-
munoliposomes was due to release of uridine at the cell
surface followed by transport and phosphorylation inside the
target cell.
It is important to understand the controlling factors that
ultimately determine the concentration and the duration of
time that this transient concentration remains at the cell
surface. These factors are (i) the rate of diffusion of the drug
away from the cell surface, (ii) the rate of release of the drug
from the liposomes, and (iii) the rate of heating. A mathe-
matical model was designed to probe the influence each of
these factors has on the transiently localized cell surface
concentration. The model describes the release of uridine
from bound immunoliposomes in terms of a concentration
pulse. The rate of uridine release must be faster than the rate
of diffusion from the cell surface in order for a transient
localized high concentration to exist at the cell surface. Once
the release rate becomes slower than the diffusion rate due to
dissipation of the concentration gradient across the liposomal
membrane, the transient concentration is rapidly diluted. For
mathematical simplicity, this model makes the following
approximations: (i) all the uridine released during the dura-
tion of the pulse is released at a constant rate; and (ii)
phosphorylation and not transport is the rate-limiting step for
the observed uptake. The concentration, C, or uridine at the
cell surface at time t can be calculated by using the following
integrated rate equation for spherically symmetrical diffusion
(30):
C(t) = erfcl 1,4irDr L(4Dt)1i
in which t is less than or equal to to, the duration of the pulse
in sec, i is the rate of release of uridine from the bound
immunoliposomes, D is the diffusion coefficient (10-5
cm2/sec), and r is the distance separating the liposome
surface from the site of uptake (5 nm). erfc is the complement
of the error function, whose numerical values can be obtained
from a standard mathematical table.
Fig. 2 shows the accumulation of phosphorylated uridine as
a function of time. Extrapolation to zero time for im-
munoliposomes yields approximately 17.5 pmol of phos-
phorylated uridine accumulated within a very short period of
time. Furthermore, the extrapolated line has a slope similar
to that of free uridine uptake. This same result can be
obtained by calculating the cell surface concentration using a
pulse time of 5 sec and a rate of release from immunolipo-
somes of 4 x 10-18 mol/sec followed by determination of the
accumulation of phosphorylated uridine by Michaelis-
Menten kinetics using a Km of 1.5 x 10-5 M and a Vmax, of 2.7
x 10'-2 mol/sec per 107 cells (21). These calculations show
that diffusion away from the cell surface is too rapid for
uridine to accumulate at the cell surface for any period oftime
after the completion of uridine release from the bound
immunoliposomes. This period is most likely determined by
the rate of release from the liposomes and the rate of heating.
The 5-sec pulse used to make this calculation is not unrea-
sonable because carboxyfluorescein release from the same
immunoliposome system bound to the same RDM4 cells was
complete within 5 sec (unpublished result).
A mathematical model was developed by Blumenthal et al.
(20) to describe the effect of the unstirred layer on the
diffusion properties of released solute from heat-sensitive
liposomes. The model was developed to explain the potential
mechanism by which carboxyfluorescein was transported
into the cell cytoplasm. This study correctly concluded that
diffusion of carboxyfluorescein away from the cell surface is
much more rapid than diffusion of the dye across the cell
membrane. This is mainly because there is no transport
system for carboxyfluorescein in the cell membrane and the
permeability of the membrane to the dye is very low. In
contrast, we have chosen in our model study an efficient
transport system-i.e., nucleoside transport-and conclude
that, if the rate of release from the liposome is comparable to
the transport rate, increased delivery efficiency can be
achieved.
Successful application of this type of controlled drug
delivery system will be dependent upon the accessibility of
the target cell or tissue and the susceptibility ofthe target area
to localized heating. Presently, the most direct application is
for treatment of tissue or cells outside of the body, such as in
autologous transplantation after immunotherapy. Alternative
administration routes such as subcutaneous and topical
administrations may facilitate the liposomal accessibility to
the target cells. Subcutaneous administration of liposomes
results in rapid clearance from the initial injection site and
accumulation in the regional lymph nodes (31), which are
amenable to localized heating. Thus, the heat-sensitive im-
Proc. Natl. Acad Sci. USA 83 (1986)
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munoliposomes may provide potentially effective delivery of
drugs for cells localized in the lymph nodes. Topical appli-
cation of liposomes has been shown to increase the retention
of localized drug concentration and minimize systemic ab-
sorption (32). Heat-sensitive immunoliposomes could serve
to fine tune the steady-state localized concentration by
regulating release of the drug through temperature control.
In conclusion, our results demonstrate the feasibility of
using heat-sensitive immunoliposomes as a controlled release
system. Furthermore, it demonstrates the advantage of this
type of drug delivery over that of nontargeted liposomes and
free drug, thus increasing the potential of liposomes as a
targeted drug delivery system.
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